Replimune Group, Inc. (REPL)

USD 11.66

(-0.51%)

Market Cap (In USD)

878.47 Million

Revenue (In USD)

-

Net Income (In USD)

-215.79 Million

Avg. Volume

700.81 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.92-17.0
PE
-
EPS
-
Beta Value
1.193
ISIN
US76029N1063
CUSIP
76029N106
CIK
1737953
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sushil Patel Ph.D.
Employee Count
-
Website
https://www.replimune.com
Ipo Date
2018-07-20
Details
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.